Becker Muscular Dystrophy – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Becker
Muscular Dystrophy – Pipeline Review, H1 2019” drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Becker Muscular Dystrophy – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for Becker
Muscular Dystrophy and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I and Preclinical stages are 1, 3, 2 and 1 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Becker Muscular Dystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Becker Muscular
  Dystrophy (Genetic Disorders) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Becker Muscular
  Dystrophy (Genetic Disorders) therapeutics and enlists all their major
  and minor projects.
• The pipeline guide evaluates Becker Muscular Dystrophy (Genetic
  Disorders) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Becker Muscular Dystrophy – Overview
4. Becker Muscular Dystrophy – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Products under Development by Companies
8. Becker Muscular Dystrophy – Therapeutics Assessment
9. Assessment by Target
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type

Becker Muscular Dystrophy – Companies Involved in Therapeutics
Development

• Catabasis Pharmaceuticals Inc
• Italfarmaco SpA
• Milo Biotechnology LLC
• PTC Therapeutics Inc
• ReveraGen BioPharma Inc

Becker Muscular Dystrophy – Drug Profiles

• ARM-210 – Drug Profile
• ataluren – Drug Profile
• edasalonexent – Drug Profile
• epicatechin – Drug Profile
• givinostat – Drug Profile
• vamorolone – Drug Profile

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gprkq0

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Musculoskeletal
Disorders Drugs